NCT06973668 is a Phase 2 clinical trial of Mycophenolate Mofetil in AML, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06973668?

NCT06973668 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06973668?

Interventions in NCT06973668: Mycophenolate Mofetil, Ruxolitinib.

Is NCT06973668 still recruiting?

NCT06973668 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT06973668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

Recruiting now Phase 2 Last updated 16 April 2026

What this trial tests

Phase 2 trial testing Mycophenolate Mofetil in AML in 80 participants. Currently enrolling.

Timeline

22 July 2025

Primary endpoint
31 January 2028

31 January 2030

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	22 July 2025
Primary completion	31 January 2028
Estimated completion	31 January 2030
Sites	1 location across United States

Drugs / interventions tested

Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

AML — all drugs for AML →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 65 to 75, any sex, with AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mycophenolate Mofetil

Trials testing the same drug.

NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07524530 — Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers · Phase 2 · not yet recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other recruiting trials for AML

Currently open trials in the same condition.

NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
NCT06972641 — Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 2, PHASE3 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06973668 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06973668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing